참고문헌
- Bleiberg, H. and Rothenberg, M.L. (1996): CPT-11: From DNA topology to clinical activity. Semi. Oncol., 23, 1-50
- Bozec, L., Bierling, P, Fromont, P, Levi, F., Debat, P, Cvitkovic, E. and Misset, J.L. (1998): Irinotecan-induced immune thrombocytopenia. Ann. Oncol., 9, 453-455
- Cass, I., Kuo, D.Y., Fields, AL., Runowicz, C.D. and Goldberg, G.L. (1998): Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecol. Oncol., 69, 175-178
- Dahut, W, Harolod, N., Takimototo, C., Allegra, C., Chen, A, Hamilton, J.M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, Wand Grem, J. (1996): Phase I and pharmacokinetic study of 9aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Glin. Oncol., 14, 1236-1244
- Edelman, E.R. and Karnovsky, M.J. (1994): Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation, 89, 770-776 https://doi.org/10.1161/01.CIR.89.2.770
- Evans, J.G. and Kerry, P.J. (2000): Common pathological findings in continuous infusion studies. In: Guy healing and David Smith (eds.) Handbook of preclinical continuous intravenous infusion. Taylor & Francis, pp 253-264
- Flynn, J.L., Chan, J., Triebold, K.J., Dalton, O.K., Stewart, T.A. and Bloom, B.R. (1993): An essential role for interferon gamma in resistance to mycobacterium tuberculosis infection. Journal of Experimental Medicine, 178, 2249-2254 https://doi.org/10.1084/jem.178.6.2249
- Fujitani, T., Tada, Y and Yoneyama, M. (2004): Chlorpropham-induced splenotoxicity and its recovery in rats. Food Chem. Toxicol., 42, 1469-1477
- Gargosky, S.E., Tapanainen, P. and Rosenfeld, R.G. (1994): Administration of growth hormone (GH), but not insulinlike growth factor-I (IGF-I), by continuous infection can induced the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology, 134, 2267-2276 https://doi.org/10.1210/en.134.5.2267
-
Greaves, P. (2000): Digestive system I, In: Histopathology of preclinical toxicity studies (
$2^{nd}$ eds) Elsevier Science, pp. 398-401 - Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T. and Block, J.B. (1970): Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470
- Hertzberg, R.P., Caranfa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K. and Kingsbury, WD. (1989): Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32, 715-720 https://doi.org/10.1021/jm00123a038
- Jung, L.L. and Zamboni, WC. (2001): Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it ? Drug. Resistance Updates, 4, 273-288
- Kasahara, K., Nishikawa, A., Furukawa, F., Ikezaki, S., Tanakamaru, Z., Lee, I.S., Imazawa, T. and Hirose, (2002): A chronic toxicity study of josamycin in F344 rats. Food Chem. Toxicol., 40, 1017-1022.
- Kim, C.Y., Imai, Y, Ito, K., Hashimoto, J., Nobunaga, T., Satoh, H. and Abe, K. (1996): Analysis of circadian variation of blood pressure and heart rate in dexamethasoneinduced hypertensive rats. Clin. Exper. Hypertension, 18, 65-76
- Kolimannsberger, C., Mross, K., Jakob, A, Kanz, L. and Bokemyer, C. (1999): Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1-12 https://doi.org/10.1159/000011923
- Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y., Jew, S.S., Park, J.G. and Hong, C.I. (1998): Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590.
- Moertel, C.G., Schutt, AJ., Reitmeier, R.J. and Hahn, R.G. (1972): Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101
- Pizzolato, J.F. and Saltz, L.B. (2003): The camptothecins. Lancet, 361, 2235-2242
- Rothenberg, M.L. (1997): Topoisomerase I inhibitors: review and update. Ann. Oncol., 8, 837-855
- Slichenmyer, WJ. and Rowinsky, E.K. (1993): The current status of amptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291 https://doi.org/10.1093/jnci/85.4.271
- Takimoto, C.H., Wright, J. and Arbuck, S.G. (1998): Clinical applications of the camptothecins. Biochirn. Biophys. Acta, 1400,107-119
- Thompson, J., Stewart, C.F. and Houghton, P.J. (1998): Animal models for studyinq the action of topoisomerase I targeted drugs. Biochim. Biophys Acta, 1400, 301-319
- Toti, P., De Felice, C., Stumpo, M., Schrfeld, K., Di Leo, L., Vatti, R., Bianciardi, G., Buonocore, G., Seemayer, TA and Luzi, P. (2000): Acute thymic involution in fetuses and neonates with chorioamnionitis. Hum. Pathol., 31, 1121-1128
- Tomas, F.M., Lemmey, A.B., Read, L.C. and Ballard, F.J. (1996): Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J. of Endocrinology, 150, 77-84 https://doi.org/10.1677/joe.0.1500077
- Wall, ME, Wani, M.C. and Cook, C.E. (1966): Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3890 https://doi.org/10.1021/ja00968a057